Evidence map›Paper›PMID 28542926›Full record

Trial reportJournal of the American Geriatrics Society2017

Effect of Spironolactone on Exercise Tolerance and Arterial Function in Older Adults with Heart Failure with Preserved Ejection Fraction.

Bharathi Upadhya, William G Hundley, Peter H Brubaker, Timothy M Morgan, Kathryn P Stewart, Dalane W Kitzman

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Geriatrics Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 10 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 10 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. The effect of spironolactone on diastolic function in haemodialysis patients.The international journal of cardiovascular imaging · 2021
    Trial
  13. Trial
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Bharathi UpadhyaCardiovascular Medicine Section, Department of Internal Medicine, School of Medicine, Wake Forest University, Winston-Salem, North Carolina.
William G HundleyCardiovascular Medicine Section, Department of Internal Medicine, School of Medicine, Wake Forest University, Winston-Salem, North Carolina.
Peter H BrubakerDepartment of Health and Exercise Science, Wake Forest University, Winston-Salem, North Carolina.
Timothy M MorganDivision of Public Health Sciences, School of Medicine, Wake Forest University, Winston-Salem, North Carolina.
Kathryn P StewartCardiovascular Medicine Section, Department of Internal Medicine, School of Medicine, Wake Forest University, Winston-Salem, North Carolina.
Dalane W KitzmanCardiovascular Medicine Section, Department of Internal Medicine, School of Medicine, Wake Forest University, Winston-Salem, North Carolina.
Wake Forest University · US

Funding

Wake Forest Claude D. Pepper OAIC - RenewalP30AG021332 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Jamie Nicole Justice · 2002 to 2026
$36.4M
Wake Forest Clinical and Translational Science AwardUL1TR001420 · NCATS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ARD, JAMY D, FOLEY, KRISTIE L · 2015 to 2023
$32.3M
Exercise Intolerance in Older HFPEF PatientsR01AG018915 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI KITZMAN, DALANE W · 2001 to 2019
$5.2M
Exercise Intolerance in Elderly Diastolic Heart FailureR37AG018915 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI KITZMAN, DALANE W · 2005 to 2013
$3.4M
NCATS NIH HHS UL1 TR001420NIA NIH HHS P30 AG021332NIA NIH HHS R01 AG018915NIA NIH HHS R37 AG018915
6 · The paper itself

Abstract

objectivesTo evaluate the effects of an aldosterone antagonist on exercise intolerance in older adults with heart failure and preserved ejection fraction (HFpEF).

designRandomized, placebo-controlled, double-blind trial.

settingAcademic medical center, Winston-Salem, North Carolina.

participantsOlder adults (N = 80, aged 71 ± 1; 80% female) with stable compensated HFpEF and controlled blood pressure (BP). MEASUREMENTS: Participants were randomized into a 9-month treatment of spironolactone 25 mg/d vs placebo. Assessments were peak exercise oxygen consumption (VO

resultsSeventy-one participants completed the trial: 37 in the spironolactone group and 34 in the placebo group. Adherence according to pill count was excellent (spironolactone 95%, placebo 97%). Mean spironolactone dose was 24.3 ± 2.9 mg/d and was well tolerated. Spironolactone significantly reduced systolic and diastolic BP at rest and peak exercise. At 9-month follow-up, baseline-adjusted peak VO

conclusionIn older adults with stable compensated HFpEF, 9 months of spironolactone 25 mg/d was well tolerated and reduced BP but did not improve exercise capacity, quality of life, LV mass, or arterial stiffness.

Indexed as

AgedAged, 80 and overCoronary VesselsDouble-Blind MethodEchocardiographyExercise TestExercise ToleranceFemaleHeart Failure, DiastolicHumansMaleMineralocorticoid Receptor AntagonistsRisk AssessmentSpironolactoneStroke VolumeMineralocorticoid Receptor AntagonistsSpironolactoneagingaldosterone antagonistarterial functionexercise toleranceheart failure

Identifiers

PMID28542926
PMCPMC5681414
OpenAlexW2614496641

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.